{"id":26179,"date":"2025-02-02T20:33:52","date_gmt":"2025-02-02T20:33:52","guid":{"rendered":"https:\/\/sunsci.io\/?page_id=26179"},"modified":"2025-07-27T10:08:38","modified_gmt":"2025-07-27T10:08:38","slug":"vigelan","status":"publish","type":"page","link":"https:\/\/sunsci.io\/en\/vigelan\/","title":{"rendered":"Vigelan"},"content":{"rendered":"\t\t
\n\t\t\t\t
\n\t\t\t\t\t
\n\t\t
\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t
\n\n\t\t\t\t\t\t
\n\t\t\t\t\n\t\t\t\t<\/path><\/svg>\t\t\t\t<\/a>\n\t\t\t<\/div>\n\t\t\t\n\t\t\t\t\t\t
\n\n\t\t\t\t\t\t\t\t\t

\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tBack\t\t\t\t\t\t<\/a>\n\t\t\t\t\t<\/h3>\n\t\t\t\t\n\t\t\t\t\n\t\t\t<\/div>\n\t\t\t\n\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t
\n\n\t\t\t\n\t\t\t
\n\t\t\t\t

Retatrutide
\n<\/h4> \n\t\t\t\t\t\t\t<\/div>\n\n\t\t\t\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t
\n\n\t\t\t\n\t\t\t
\n\t\t\t\t

<\/h4> \n\t\t\t\t\t\t\t<\/div>\n\n\t\t\t\t\t\t\t
\n\t\t\t\t\t

It is intended for the following purposes:
\u2714<\/strong><\/span> As a complement to diet and physical activity to enhance glycemic control in adults with type 2 diabetes mellitus.
\u2714<\/strong><\/span> To lower the risk of major cardiovascular events in patients with type 2 diabetes and diagnosed cardiovascular disease.
\u2714<\/strong><\/span> To reduce liver fat infiltration and decrease inflammation markers associated with fatty liver.
\u2714<\/strong><\/span> To promote weight loss and reduce body fat, which not only improves health outcomes but also serves as a measure of treatment efficacy for type 2 diabetes management.<\/p>\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t

\n\t\t\t\t\t
\n\t\t
\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\"\"\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t
\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\"\"\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t
\n\n\t\t\t\n\t\t\t
\n\t\t\t\t

Retatrutide<\/h4> \n\t\t\t\t\t\t\t<\/div>\n\n\t\t\t\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t
\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t
\n\n\t\t\t\n\t\t\t
\n\t\t\t\t

<\/h4> \n\t\t\t\t\t\t\t<\/div>\n\n\t\t\t\t\t\t\t
\n\t\t\t\t\t

\u0421ontains Retatrutide, a multi-functional peptide with triple receptor agonist activity targeting GIP (glucose-dependent insulinotropic polypeptide), GLP-1, and glucagon receptors.<\/p>\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t

\n\t\t\t\t
\n\t\t\t\t\t\t\t
\n\n\t\t\t\n\t\t\t
\n\t\t\t\t

Mechanism of Action
\n<\/h4> \n\t\t\t\t\t\t\t<\/div>\n\n\t\t\t\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t
\n\n\t\t\t\n\t\t\t
\n\t\t\t\t

<\/h4> \n\t\t\t\t\t\t\t<\/div>\n\n\t\t\t\t\t\t\t
\n\t\t\t\t\t

Retatrutide is a 39-amino acid peptide that simultaneously activates the glucagon receptor (GCGR), GIP receptor (GIPR), and GLP-1 receptor (GLP-1R). It features a C20 fatty diacid group that enhances its half-life and metabolic stability.<\/p>

The structure of Retatrutide includes several modifications that resist degradation by dipeptidyl peptidase-4 (DPP4), enhancing its bioactivity. By acting on multiple receptors, Retatrutide improves insulin secretion, regulates glucagon production, and helps maintain stable blood sugar levels while promoting weight loss through reduced food intake and improved metabolic efficiency.<\/p>\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t

\n\t\t\t\t\t
\n\t\t
\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t
\n\n\t\t\t\n\t\t\t
\n\t\t\t\t

Pharmacodynamics
\n<\/h4> \n\t\t\t\t\t\t\t<\/div>\n\n\t\t\t\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t
\n\n\t\t\t\n\t\t\t
\n\t\t\t\t

<\/h4> \n\t\t\t\t\t\t\t<\/div>\n\n\t\t\t\t\t\t\t
\n\t\t\t\t\tRetatrutide influences several metabolic pathways that collectively enhance glycemic control and facilitate weight management in individuals with type 2 diabetes:

\u2022Insulin Secretion & Sensitivity: The drug boosts both first- and second-phase insulin release while increasing insulin sensitivity, thus improving glucose metabolism.

\u2022Glucagon Modulation: Retatrutide competes with the natural ligand at glucagon receptors, reducing glucagon secretion by approximately 70%, aiding in better blood sugar regulation.

\u2022Gastric Emptying: By delaying gastric emptying, Retatrutide slows glucose absorption after meals, leading to more gradual blood sugar increases and reduced appetite.

\u2022Liver Fat and Inflammation Reduction: Clinical studies have demonstrated that Retatrutide decreases hepatic fat content within 24 weeks, with further improvements by week 48, including reduced markers of insulin resistance and liver inflammation.\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t
\n\n\t\t\t\n\t\t\t
\n\t\t\t\t

Clinical Research Results
\n<\/h4> \n\t\t\t\t\t\t\t<\/div>\n\n\t\t\t\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t
\n\n\t\t\t\n\t\t\t
\n\t\t\t\t

<\/h4> \n\t\t\t\t\t\t\t<\/div>\n\n\t\t\t\t\t\t\t
\n\t\t\t\t\t

The TRIUMPH clinical trial (Phases 1 and 2) assessed the efficacy of Retatrutide in managing chronic weight issues, sleep apnea, and osteoarthritis in obese and overweight individuals.<\/p>

\u2022At 24 weeks, weight loss averaged up to 17.5% (41.2 lbs or 18.7 kg).<\/p>\u2022By 48 weeks, the weight reduction reached 24.2% (57.8 lbs or 26.2 kg) in participants receiving 12 mg weekly.

\u00a0Participants were stratified by BMI and sex and randomly assigned to receive varying doses of Retatrutide (1 mg, 4 mg, 8 mg, or 12 mg) or placebo. All participants received structured lifestyle counseling in line with U.S. dietary and physical activity guidelines.\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t

\n\t\t\t\t
\n\t\t\t\t\t\t\t
\n\n\t\t\t\n\t\t\t
\n\t\t\t\t

Key Outcomes:
\n<\/h4> \n\t\t\t\t\t\t\t<\/div>\n\n\t\t\t\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t
\n\n\t\t\t\n\t\t\t
\n\t\t\t\t

<\/h4> \n\t\t\t\t\t\t\t<\/div>\n\n\t\t\t\t\t\t\t
\n\t\t\t\t\t\u2022Weight reduction at 24 weeks:

\u20227.2% for the 1 mg group

\u202213.9% for the 4 mg group with a starting dose of 4 mg

\u202217.9% for the 8 mg group with a starting dose of 4 mg

\u202217.5% for the 12 mg group

\u20221.6% for the placebo group

\u2022Weight reduction at 48 weeks:

\u20228.7% for the 1 mg group

\u202217.8% for the 4 mg group with a starting dose of 4 mg

\u202223.9% for the 8 mg group with a starting dose of 4 mg

\u202224.2% for the 12 mg group

\u20222.1% for the placebo group\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t
\n\n\t\t\t\n\t\t\t
\n\t\t\t\t

Additional Observations:<\/h4> \n\t\t\t\t\t\t\t<\/div>\n\n\t\t\t\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t
\n\n\t\t\t\n\t\t\t
\n\t\t\t\t

<\/h4> \n\t\t\t\t\t\t\t<\/div>\n\n\t\t\t\t\t\t\t
\n\t\t\t\t\t\u2022 92% to 100% of participants achieved a \u22655% weight reduction depending on dose.

\u2022Participants experienced significant improvements in cardiometabolic markers, including reductions in waist circumference, blood pressure, and LDL cholesterol.

\u202272% of those with prediabetes reverted to normoglycemia by the end of the trial.

\u00a0These findings highlight Retatrutide\u2019s efficacy in surpassing typical weight-loss targets set by other anti-obesity treatments, prompting potential re-evaluation of weight-loss goals in clinical guidelines.\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t
\n\n\t\t\t\n\t\t\t
\n\t\t\t\t

Dosage and Administration
\n<\/h4> \n\t\t\t\t\t\t\t<\/div>\n\n\t\t\t\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t
\n\n\t\t\t\n\t\t\t
\n\t\t\t\t

<\/h4> \n\t\t\t\t\t\t\t<\/div>\n\n\t\t\t\t\t\t\t
\n\t\t\t\t\tStarting Dosage:<\/strong>

\u20222 mg subcutaneously once weekly to reduce gastrointestinal side effects and assess individual tolerance.

\u00a0Titration:<\/strong>

\u2022Increase to 4 mg weekly after 2 weeks.

\u2022Further dosage adjustments may be made in 1 mg increments every 2 weeks based on patient needs, up to a maximum dose of 8 mg per week.

\u00a0Missed Dose Instructions:<\/strong>

\u2022Administer the missed dose within 96 hours. If more than 4 days have passed, skip the dose and resume the regular schedule.

\u00a0Injection Guidelines:<\/strong>

\u2022Inject subcutaneously into the abdomen, thigh, or upper arm. Rotate injection sites to prevent irritation.

\u2022When used alongside insulin, administer injections separately. Do not mix Retatrutide with insulin.\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t
\n\n\t\t\t\n\t\t\t
\n\t\t\t\t

Contraindications and Side Effects
\n<\/h4> \n\t\t\t\t\t\t\t<\/div>\n\n\t\t\t\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t
\n\n\t\t\t\n\t\t\t
\n\t\t\t\t

<\/h4> \n\t\t\t\t\t\t\t<\/div>\n\n\t\t\t\t\t\t\t
\n\t\t\t\t\tDo not use Vigelan\u00ae in patients with:<\/strong>

\u2022A personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN 2).

\u2022Known hypersensitivity to Retatrutide or its components.

\u00a0Common Adverse Effects:<\/strong>

\u2022Decreased appetite, nausea, constipation, and diarrhea.

\u2022Transient gastrointestinal issues, which are dose-dependent and primarily occur during dose escalation.

\u2022Mild increases in heart rate.\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t
\n\n\t\t\t\n\t\t\t
\n\t\t\t\t

<\/h4> \n\t\t\t\t\t\t\t<\/div>\n\n\t\t\t\t\t\t\t
\n\t\t\t\t\t

\u26a0 Warning!<\/span><\/p>

This medication is not intended for patients with type 1 diabetes.<\/p>\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t

\n\t\t\t\t\t
\n\t\t
\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\"\"\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t